Table 1 Baseline demographic and clinical characteristics of enrolled patients in the analysis
|  | Pyrotinib monotherapy group (n = 38) | Pyrotinib plus capecitabine group (n = 36) | χ2 | P value |
|---|---|---|---|---|
Median age, years (range) | Â | Â | 0.122 | 0.727 |
  ≤ 45 | 16(42.1) | 13(46.4) |  |  |
 >45 | 22(57.9) | 15(53.6) |  |  |
Menstrual status | Â | Â | 0.041 | 0.840 |
 Premenopausal | 24(63.2) | 17(60.7) |  |  |
 Postmenopausal | 14(36.8) | 11(39.3) |  |  |
ECOG | Â | Â | 2.507 | 0.113 |
 0 | 35(92.1) | 22(78.6) |  |  |
 1 | 3(7.9) | 6(21.4) |  |  |
ER status | Â | Â | 1.861 | 0.173 |
 Positive | 20(52.6) | 10(35.7) |  |  |
 Negative | 18(47.4) | 18(64.3) |  |  |
PR status | Â | Â | 3.821 | 0.051 |
 Positive | 20(52.6) | 8(28.6) |  |  |
 Negative | 18(47.4) | 20(71.4) |  |  |
Tumor site | Â | Â | 0.143 | 0.705 |
 Visceral | 30(78.9) | 21(75.0) |  |  |
 Nonvisceral | 8(21.1) | 7(25.0) |  |  |
Prior taxane treatment, n (%) | 38(100) | 27(96.4) | 1.378 | 0.240 |
Prior anthracycline treatment, n (%) | 35(92.1) | 24(85.7) | 0.694 | 0.405 |
Prior trastuzumab treatment, n (%) | Â | Â | 0.482 | 0.923 |
 Trastuzumab-pretreated for metastatic disease only | 12(31.6) | 8(28.6) |  |  |
 Trastuzumab-pretreated in the adjuvant/neoadjuvant setting only | 10(26.3) | 6(21.4) |  |  |
 Trastuzumab-pretreated in both adjuvant/neoadjuvant setting and metastatic setting | 4(10.5) | 3(10.7) |  |  |
 Non | 12(31.6) | 11(39.3) |  |  |